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A meta-analysis of two high-risk
prospective cohort studies reveals autism-
specific transcriptional changes to
chromatin, autoimmune, and
environmental response genes in umbilical
cord blood
Charles E. Mordaunt1†, Bo Y. Park2†, Kelly M. Bakulski3, Jason I. Feinberg4, Lisa A. Croen5, Christine Ladd-Acosta4,
Craig J. Newschaffer6, Heather E. Volk4, Sally Ozonoff7, Irva Hertz-Picciotto8, Janine M. LaSalle1*† ,
Rebecca J. Schmidt8† and M. Daniele Fallin4†
Abstract
Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects more than 1% of
children in the USA. ASD risk is thought to arise from both genetic and environmental factors, with the perinatal
period as a critical window. Understanding early transcriptional changes in ASD would assist in clarifying disease
pathogenesis and identifying biomarkers. However, little is known about umbilical cord blood gene expression
profiles in babies later diagnosed with ASD compared to non-typically developing and non-ASD (Non-TD) or typically
developing (TD) children.
Methods: Genome-wide transcript levels were measured by Affymetrix Human Gene 2.0 array in RNA from cord blood
samples from both the Markers of Autism Risk in Babies-Learning Early Signs (MARBLES) and the Early Autism Risk
Longitudinal Investigation (EARLI) high-risk pregnancy cohorts that enroll younger siblings of a child previously diagnosed
with ASD. Younger siblings were diagnosed based on assessments at 36months, and 59 ASD, 92 Non-TD, and 120 TD
subjects were included. Using both differential expression analysis and weighted gene correlation network analysis, gene
expression between ASD and TD, and between Non-TD and TD, was compared within each study and via meta-analysis.
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Results: While cord blood gene expression differences comparing either ASD or Non-TD to TD did not reach genome-
wide significance, 172 genes were nominally differentially expressed between ASD and TD cord blood (log2(fold
change) > 0.1, p < 0.01). These genes were significantly enriched for functions in xenobiotic metabolism, chromatin
regulation, and systemic lupus erythematosus (FDR q < 0.05). In contrast, 66 genes were nominally differentially
expressed between Non-TD and TD, including 8 genes that were also differentially expressed in ASD. Gene coexpression
modules were significantly correlated with demographic factors and cell type proportions.
Limitations: ASD-associated gene expression differences identified in this study are subtle, as cord blood is not the
main affected tissue, it is composed of many cell types, and ASD is a heterogeneous disorder.
Conclusions: This is the first study to identify gene expression differences in cord blood specific to ASD through a meta-
analysis across two prospective pregnancy cohorts. The enriched gene pathways support involvement of environmental,
immune, and epigenetic mechanisms in ASD etiology.
Keywords: Autism spectrum disorder, Neurodevelopment, Umbilical cord blood, Gene expression, Meta-analysis,
Prospective study, Microarray, Chromatin, Environment, Perinatal
Background
Autism spectrum disorder (ASD) is a neurodevelop-
mental disorder characterized by impaired social inter-
action and restricted and repetitive behaviors. Heritability
of ASD risk has been well established with twin and family
studies and is estimated at 52% [1–3]. While rare variants
with large effects explain a relatively small proportion of
all ASD cases, heritable common variants with individually
minor effects contribute substantially to ASD risk [4]. Ac-
cumulating lines of evidence suggest that ASD arises from
complex interactions between heterogeneous genetic and
environmental risk factors. Gene expression levels are in-
fluenced by both genetic and environmental factors and
determine the functional responses of cells and tissues.
Postmortem brain gene expression studies have guided
understanding of ASD pathophysiology and show evi-
dence of changes in gene coexpression and enrichment in
immune response and neuronal activity functions [5, 6].
Peripheral blood gene expression studies in children and
adults using whole blood and in specific cell types (natural
killer (NK) cell and lymphocytes) observed enrichment of
immune and inflammatory processes in differential gene
expression associated with ASD [7, 8]. Recent efforts have
been focused on identifying how genetic risk factors
converge into one or more unifying pathways and patho-
physiological mechanisms [9, 10]. Yet, the majority of this
work to date relies on postmortem or postsymptom
timing of sample collection, rather than prospective
assessment of gene expression.
Converging evidence suggests that most of the
changes in the brain associated with ASD are initiated
during prenatal brain development [11, 12], but the
complete nature of these changes remains unknown.
Umbilical cord blood captures fetal blood as well as
the exchanges across the fetoplacental unit and
provides a distinct insight into prenatal development.
A unique cell mixture is represented in umbilical cord
blood, including hematopoietic stem cells, B cells, NK
cells, T cells, monocytes, granulocytes, and nucleated
red blood cells [13]. Cord blood gene expression would
reflect the immune response as well as endocrine and
cellular communication essential for fetal development
near the time of birth.
While several studies have previously examined child
blood gene expression differences in ASD [8, 14–20], this
is the first study to take advantage of cord blood samples
collected from two prospective studies (Markers of Aut-
ism Risk in Babies-Learning Early Signs (MARBLES) and
the Early Autism Risk Longitudinal Investigation (EARLI))
in order to assess the perinatal transcriptional changes
that precede ASD diagnosis in high-risk children [21, 22].
The subjects in this study are all siblings of children with
ASD and thus have a 13-fold increased risk for ASD com-
pared to the general population [23]. They are also at a
higher risk for non-typical neurodevelopment, including
deficits in attention and behavior. We measured cord
blood gene expression levels using the Affymetrix Human
Gene 2.0 array and compared gene-level differential
expression, gene set enrichment, and gene coexpression
networks across ASD, non-typically developing (Non-TD)
and neurotypical children (Additional file 1: Figure S1).
Study-level results were then combined in a meta-analysis
to investigate cord blood transcriptional dysregulation in
ASD.
Methods
Sample population and biosample collection
MARBLES
The MARBLES study recruits Northern California
mothers from lists of children receiving services
through the California Department of Developmental
Services who have a child with confirmed ASD and are
planning a pregnancy or are pregnant with another
child. Inclusion criteria for the study were as follows:
Mordaunt et al. Molecular Autism           (2019) 10:36 Page 2 of 21
(1) mother or father has one or more biological child(ren)
with ASD; (2) mother is 18 years or older; (3) mother is
pregnant; (4) mother speaks, reads, and understands
English sufficiently to complete the protocol and the youn-
ger sibling will be taught to speak English; and (5) mother
lives within 2.5 h of the Davis/Sacramento region at time of
enrollment. As described in more detail elsewhere [21],
demographic, diet, lifestyle, environmental, and medical in-
formation were prospectively collected through telephone-
assisted interviews and mailed questionnaires throughout
pregnancy and the postnatal period. Mothers were provided
with sampling kits for cord blood collection prior to deliv-
ery. MARBLES research staff made arrangements with
obstetricians/midwives and birth hospital labor and delivery
staff to assure proper sample collection and temporary
storage. Infants received standardized neurodevelopmental
assessments beginning at 6months, as described below,
and concluding at 3 years of age. For this study, all children
actively enrolled by March 1, 2017 (n = 347), with umbilical
cord blood collected in a PAXgene Blood RNA tube (n =
262, 76%) were included.
EARLI
The EARLI study is a high-risk pregnancy cohort that
recruited and followed pregnant mothers who had an
older child diagnosed with ASD through pregnancy,
birth, and the first 3 years of life. EARLI families were
recruited at four EARLI Network sites (Drexel/Chil-
dren’s Hospital of Philadelphia, Johns Hopkins/Kennedy
Krieger Institute, University of California (UC) Davis,
and Kaiser Permanente Northern California) in three
distinct US regions (Southeast Pennsylvania, Northeast
Maryland, and Northern California). In addition to hav-
ing a biological child with ASD confirmed by EARLI
study clinicians, to be eligible, mothers also had to com-
municate in English or Spanish and, at recruitment,
meet the following criteria: be 18 years or older, live
within 2 h of a study site, and be < 29 weeks pregnant.
The design of the EARLI study is described in more de-
tail in Newschaffer et al. [22]. EARLI research staff made
arrangements with obstetricians/midwives and birth
hospital labor and delivery staff to ensure proper cord
blood sample collection and temporary storage. The
development of children born into the cohort was
closely followed through age 3 years. For this study, 212
infants born into EARLI as a singleton birth and
followed to 1 year of age were considered for inclusion.
Of the 212 infants, 97 were excluded because they were
either missing umbilical cord blood samples or outcome
measures at 36 months, leaving a final sample of 115.
Diagnostic outcomes
In both studies, development was assessed by trained,
reliable examiners. Diagnostic assessments at 3 years
included the gold standard Autism Diagnostic Obser-
vation Schedule (ADOS) [24, 25], the Autism Diagnos-
tic Interview-Revised (ADI-R) [26] conducted with
parents, and the Mullen Scales of Early Learning
(MSEL) [27], a test of cognitive, language, and motor
development. Participants were classified into one of
three outcome groups, ASD, typically developing (TD),
and Non-TD, based on a previously published algo-
rithm that uses ADOS and MSEL scores [28, 29]. Chil-
dren with ASD outcomes had scores over the ADOS
cutoff and met DSM-5 criteria for ASD. The Non-TD
group was defined as children with low MSEL scores
(i.e., two or more MSEL subscales that are more than
1.5 standard deviations (SD) below average or at least
one MSEL subscale that was more than 2 SD below
average), elevated ADOS scores (i.e., within 3 points of
the ASD cutoff), or both. Children with TD outcomes
had all MSEL scores within 2 SD and no more than
one MSEL subscale 1.5 SD below the normative mean
and scores on the ADOS at least 3 or more points
below the ASD cutoff.
Demographic characteristics
In both the MARBLES and EARLI studies, demographic
information was prospectively collected through in-
person and telephone-assisted interviews and mailed
questionnaires throughout pregnancy and the postnatal
period. Cotinine was measured in maternal urine during
pregnancy, and maternal smoking was identified if the
concentration of cotinine was > 50 ng/mL [30]. Within
each study, demographic characteristics were stratified
by diagnostic outcome and compared using Fisher’s
exact test for categorical variables and one-way ANOVA
for continuous variables.
RNA isolation and expression assessment
In both MARBLES and EARLI, umbilical cord blood was
collected at the time of birth in PAXgene Blood RNA
Tubes with the RNA stabilization reagent (BD Biosci-
ences) and stored at − 80 °C. RNA isolation was per-
formed with the PAXgene Blood RNA Kit (Qiagen)
following the manufacturer’s protocol. RNA from 236
(90%) of the 262 MARBLES PAXgene blood samples
and all of the EARLI PAXgene blood samples met
quality control standards (RIN ≥ 7.0 and concentration ≥
35 ng/uL) and volume requirements. Total RNA was
converted to cDNA and in vitro transcribed to biotin-
labeled cRNA, which was hybridized to Human Gene
2.0 Affymetrix microarray chips by the Johns Hopkins
Sequencing and Microarray core. EARLI and MARBLES
samples were measured separately and in multiple
batches within each study. The manufacturer’s protocol
was followed for all washing, staining, and scanning pro-
cedures. The raw fluorescence data (in Affymetrix CEL
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file format) with one perfect match and one mismatched
probe in each set were analyzed using the oligo package
in R.
Data preprocessing
Within each study, signal distribution was first
assessed in perfect-match probe intensity and robust
multi-chip average (RMA) normalized data [31]. Dur-
ing the quality control step, we identified outliers using
the arrayQualityMetrics and oligo R packages [32, 33].
Outliers were excluded based on loading in principal
component 1, the Kolmogorov-Smirnov test, median
normalized unscaled standard error, and the sum of
the distances to all other arrays. For the MARBLES
study, 3 outlier samples were identified and excluded,
and another 71 children had not yet received a diagno-
sis by April 12, 2018, so were excluded; 162 samples
were normalized using RMA. For the EARLI study, 6
outliers were identified and excluded, then 109 sam-
ples were normalized using RMA. Probes were anno-
tated at the transcript level using the pd.hugene.2.0.st
R package [34], and those assigned to a gene (36,459
probes) were used in subsequent analyses.
Surrogate variable analysis
Surrogate variable analysis (SVA) was used to estimate
and adjust for unmeasured environmental, demographic,
cell type proportion, and technical factors that may have
substantial effects on gene expression using the SVA R
package [35, 36]. Twenty-one surrogate variables were
detected in normalized expression data from MARBLES
subjects for both the ASD versus TD and Non-TD
versus TD comparisons. Specific factors associated with
surrogate variables in MARBLES using linear regression
included array batch, sex, maternal BMI, gestational age,
delivery method, child ethnicity, and maternal education
(false discovery rate (FDR) q < 0.1, Additional file 1:
Figure S2a). In normalized expression data from EARLI
subjects, 11 surrogate variables were detected for the
ASD versus TD comparison, which were associated with
sex, birth weight, gestational age, and paternal age (FDR
q < 0.1, Additional file 1: Figure S3a). Twelve surrogate
variables were detected for the Non-TD versus TD com-
parison, which were associated with sex and gestational
age (FDR q < 0.1, Additional file 1: Figure S4a). Propor-
tion of variance in expression of each gene explained by
each surrogate variable was determined using the varian-
cePartition R package [37]. Median variance explained
by each surrogate variable ranged from 0.3 to 5.6% in
MARBLES (Additional file 1: Figure S2b). In EARLI,
median variance explained by each surrogate variable
ranged from 0.8 to 7.1% for the ASD versus TD
comparison and 0.5 to 7.2% for the Non-TD versus TD
comparison (Additional file 1: Figures S3b and S4b).
Differential gene expression
Differential expression was determined using the limma
package in R with diagnosis and all surrogate variables
included in the linear model [38] (Additional file 1:
Figures S5 and S6). ASD versus TD and Non-TD versus
TD differential expression results were extracted from a
single model with three levels for diagnosis for MAR-
BLES, while two pairwise models were used for EARLI,
although this did not affect the results (1 vs 2 model
meta-analysis fold change ASD vs TD Pearson’s r = 0.97,
Non-TD vs TD Pearson’s r = 0.99). Fold change and
standard error from each study were input into the
METAL command-line tool for meta-analysis using
the standard error analysis scheme with genomic con-
trol correction [39]. In this approach, the fold changes
from each study are weighted using the inverse of the
standard error. Using the meta-analyzed data, differen-
tial probes were then identified as those with a nom-
inal p value < 0.01 and an average absolute log2(fold
change) > 0.1.
Gene overlap analysis
Gene overlap analysis by Fisher’s exact test was
performed using the GeneOverlap R package [40].
Gene symbols annotated to differentially expressed
probes were compared to autism-related or blood cell
type-associated gene lists [41] for overlap relative to
all genes annotated to probes on the array. Genes with
variation previously associated with autism were
obtained from the Simons Foundation Autism Re-
search Initiative (SFARI) Gene database and a recent
genome-wide association study meta-analysis [42, 43],
while genes with expression previously associated with
autism were obtained from multiple previous reports
[6, 8, 44, 45]. Significant overlaps were those with an
FDR q value < 0.05.
Overrepresentation enrichment analysis
Differential probes identified during meta-analysis
were converted to Entrez gene IDs using the biomaRt
R package [46]. Functional enrichment of only differ-
ential probes by hypergeometric test was relative to all
probes on the array and was performed using the Web-
Gestalt online tool with default parameters for the
overrepresentation enrichment analysis method [47].
Enrichment databases included WebGestalt defaults
and also a custom database of recently evolved genes
obtained from [48]. WebGestalt default databases
queried included Gene Ontology, KEGG, WikiPath-
ways, Reactome, PANTHER, MSigDB, Human Pheno-
type Ontology, DisGeNET, OMIM, PharmGKB, and
DrugBank. Significant enrichments were those with an
FDR q value < 0.05.
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Gene set enrichment analysis
All probes included in the analysis were ranked using
meta-analysis log2(fold change) and input into the Web-
Gestalt online tool using default parameters for the
GSEA method [47]. GSEA assesses whether genes in
biologically predefined sets occur toward the top or
bottom of a ranked list of all examined genes more than
expected by chance [49]. GSEA calculates an enrichment
score normalized to the set size to estimate the extent of
non-random distribution of the predefined gene set, and
it then tests the significance of the enrichment with a
permutation test. Enrichment databases included Web-
Gestalt defaults (see above). Significant gene sets were
called as those with an FDR q value < 0.05.
Weighted gene correlation network analysis
Weighted gene correlation network analysis (WGCNA)
was performed using the WGCNA R package [50].
RMA-normalized expression data were adjusted for
batch using ComBat due to large batch effects in
MARBLES [36]. Samples were clustered with hierarch-
ical clustering using the average method and excluded
using static tree cutting with cut height set to 100,
resulting in one outlier being removed for each study
[50]. Expression data were renormalized with RMA
and adjusted for batch after removing outliers. Final
samples for WGCNA included 59 ASD (41 MARBLES/
19 EARLI), 91 Non-TD (44 MARBLES/47 EARLI), and
119 TD (76 MARBLES/43 EARLI). Signed topological
overlap matrices (TOMs) were obtained separately for
each study in a single block using the biweight midcorrela-
tion with the maximum percentile for outliers set to 0.1
and the soft-thresholding power set to 10. Study-specific
TOMs were calibrated using full quantile normalization,
and a consensus TOM was calculated as the parallel mini-
mum of the study-specific TOMs. Modules were identi-
fied using dynamic hybrid tree cutting with deepSplit set
to 4, and modules with a dissimilarity < 0.1 were merged.
Module hub probes were determined as the probe in each
module with the highest module membership. Study-
specific module eigengenes were correlated with demo-
graphic factors or estimated cell type proportions using
the biweight midcorrelation with the maximum percentile
for outliers set to 0.1 and including only pairwise-
complete observations. Study-specific correlation Z-scores
were combined in a meta-analysis using Stouffer’s method
with weights given by the square root of the sample n
[51]. p values were adjusted for all comparisons using the
FDR method. Significant correlations were called as those
with an FDR q value < 0.05.
Cell type proportion deconvolution
Estimation of cell type proportions was performed
using CIBERSORT [41]. Final samples for cell type
deconvolution were the same as for WGCNA: 59 ASD
(41 MARBLES/19 EARLI), 91 Non-TD (44 MARBLES/
47 EARLI), and 119 TD (76 MARBLES/43 EARLI).
RMA-normalized expression data was adjusted for
batch due to large batch effects in MARBLES. To cor-
respond with identifiers used by CIBERSORT, array
probes were matched to HUGO Gene Nomenclature
Committee (HGNC) gene symbols using the biomaRt
R package [46]. RMA-normalized expression data and
the default LM22 adult blood signature gene files were
input into the CIBERSORT web tool [41]. A similar
signature gene file was not available for umbilical cord
blood and so an adult reference panel was used. Rela-
tive and absolute modes were run together, with 100
permutations and without quantile normalization.
Deconvolution goodness of fit p value was < 0.05 for
all subjects. Estimated cell type proportions were
correlated with demographic factors within each study
using the biweight midcorrelation with the maximum
percentile for outliers set to 0.1 and including only
pairwise-complete observations. Study-specific correl-
ation Z-scores were combined in a meta-analysis using
Stouffer’s method with weights given by the square
root of the sample n [51]. p values were adjusted for all
comparisons using the FDR method. Significant
correlations were called as those with an FDR q value
< 0.05.
Results
Study sample characteristics
MARBLES subjects in the final analysis included 41
ASD (30 male, 11 female), 44 Non-TD (27 male, 17
female), and 77 TD subjects (40 male, 37 female).
Paternal age and gestational age were nominally asso-
ciated with diagnostic group in MARBLES, with
slightly increased paternal age and gestational age for
the ASD subjects (paternal age p = 0.02, gestational age
p = 0.04, Table 1). Other demographic characteristics
were not associated with diagnostic group among
MARBLES subjects. EARLI subjects in the final ana-
lysis included 18 ASD (13 male, 5 female), 48 Non-TD
(23 male, 25 female), and 43 TD subjects (19 male, 24
female). Child race and ethnicity and home ownership
were nominally associated with diagnostic group in
EARLI (race and ethnicity p = 0.02, home ownership
p = 0.01, Table 2). Specifically, the ASD group included
a lower proportion of white subjects and a lower rate
of home ownership. Other demographic characteristics
were not associated with diagnostic group among
EARLI subjects. In the meta-analysis, which combined
both the MARBLES and EARLI studies, gene expres-
sion was analyzed in 271 subjects, including 120 TD,
59 ASD, and 92 Non-TD subjects.
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ASD-associated differential gene expression in cord blood
We examined differential expression of single genes in
cord blood samples in association with ASD diagnosis
status at 36months. In meta-analysis, no transcripts were
differentially expressed at a conservative FDR q value <
0.05. Under the thresholds of log2(fold change) > 0.1 and
nominal p value < 0.01, 172 transcripts were differentially
expressed between ASD and TD cord blood (ASD n = 59,
TD n = 120, Fig. 1a, Additional file 2: Table S1). Among
these differential transcripts, 87 were upregulated and 85
were downregulated, and the median absolute log2(fold
change) was 0.12. The differential transcript with the
greatest absolute fold change was TUBB2A (log2(fold
change) = 0.35, standard error = 0.12, p = 4.8E−3, Fig. 1b,
Table 3). Additionally, the estimated fold changes for
differentially expressed genes were strongly correlated
between the two studies (Pearson’s r = 0.80, p < 2.2E−16),
although the fold changes of all transcripts were weakly
correlated (Pearson’s r = 0.02, p = 4.6E−4, Additional file 1:
Figure S7a). Many of the differentially expressed genes
were non-coding or uncharacterized transcripts; however,
the median expression of differentially expressed genes
was not lower than non-differentially expressed genes on
the array (MARBLES: differential = 4.70, non-differential =
4.64, p = 0.74; EARLI: differential = 4.34, non-differential =
4.19, p = 0.52; Additional file 1: Figure S8).
Table 1 Demographic characteristics of children and their parents in the MARBLES study, stratified by child diagnosis
Child 36 month outcome
ASD (n = 41) Non-TD (n = 44) TD (n = 77) p valuea
Child male gender, n (%) 30 (73.2) 27 (61.4) 40 (51.9) 0.08
Child race and ethnicity, n (%) 0.90
White (European or Middle Eastern) 19 (46.3) 18 (40.9) 38 (49.4)
Black/African-American 2 (4.9) 2 (4.5) 1 (1.3)
Asian or Pacific Islander 4 (9.8) 3 (6.8) 7 (9.1)
Hispanic White 8 (19.5) 11 (25) 19 (24.7)
Hispanic Non-White 4 (9.8) 3 (6.8) 6 (7.8)
Multiracial 4 (9.8) 7 (15.9) 6 (7.8)
Mother age (years), mean (SD)b 35.4 (5.1) 34.1 (4.3) 33.3 (4.9) 0.09
Father age (years), mean (SD)c 38.7 (5.3) 36.1 (4.8) 35.7 (6.2) 0.02k
Mother prepregnancy BMI, mean (SD)d 27.9 (7.4) 29.3 (8.3) 26.1 (6.2) 0.05
Mother type 1 diabetes, n (%)e 0 (0) 0 (0) 1 (1.3) 1.00
Mother type 2 diabetes, n (%)e 0 (0) 0 (0) 1 (1.3) 1.00
Mother gestational diabetes, n (%)f 12 (30) 6 (14.3) 11 (14.7) 0.12
Mother hypertension, n (%)e 1 (2.6) 1 (2.3) 1 (1.3) 1.00
Mother preeclampsia, n (%)g 2 (5.1) 4 (10) 2 (2.7) 0.29
Mother smoking by urine cotinine, n (%)h 4 (17.4) 1 (4.3) 1 (2.9) 0.12
Mother bachelor’s degree +, n (%) 18 (43.9) 19 (43.2) 40 (51.9) 0.57
Father bachelor’s degree +, n (%) 21 (51.2) 19 (43.2) 39 (50.6) 0.69
Own home, n (%)i 21 (55.3) 25 (58.1) 48 (63.2) 0.69
Cesarean delivery, n (%)j 11 (26.8) 17 (38.6) 31 (41.3) 0.28
Gestational age (weeks), mean (SD) 39.4 (1.1) 39 (1.3) 38.7 (1.4) 0.04k
Birth weight (kg), mean (SD) 3.5 (0.4) 3.5 (0.4) 3.4 (0.5) 0.52
ASD autism spectrum disorder, Non-TD non-typically developing, TD typically developing
ap values from Fisher’s exact test for categorical variables and one-way ANOVA for continuous variables
bFrequency missing = 1 ASD
cFrequency missing = 2 ASD, 1 TD
dFrequency missing = 1 ASD, 1 TD
eFrequency missing = 2 ASD, 1 Non-TD, 1 TD
fFrequency missing = 1 ASD, 2 Non-TD, 2 TD
gFrequency missing = 2 ASD, 4 Non-TD, 2 TD
hFrequency missing = 18 ASD, 21 Non-TD, 42 TD
iFrequency missing = 3 ASD, 1 Non-TD, 1 TD
jFrequency missing = 2 TD
kNominally-significant association with child diagnosis
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Several differentially expressed genes in cord blood
overlapped with genes previously associated with ASD
in genetic or gene expression studies, although the
overlap was not statistically significant (FDR q > 0.05,
Additional file 1: Figure S9, Additional file 2: Table
S2). Specifically, SLC7A3, VSIG4, and MIR1226 have
been associated with ASD in genetic studies [42, 43],
while SNORD104, OR2AG2, and DHX30 were differen-
tially expressed in the same direction in ASD in gene
expression studies [8, 44]. Further, GFI1, GPR171,
KIR2DL4, PTGIR, and TRPM6 were differentially
expressed in ASD cord blood and are also differentially
expressed in specific blood cell types, including natural
killer cells and T cells, although a significant enrich-
ment was not observed (q > 0.05, Additional file 1:
Figure S10, Additional file 2: Table S3) [41].
Overrepresentation enrichment analysis, which looks
for overlap of only differentially expressed genes with
biologically predefined gene lists, revealed that ASD
differential transcripts were significantly enriched for
functions in the response to toxic substances (TRPM6,
CYP1A1, FOS, GCH1, AC012476.1, RAD51, and AQP10,
fold enrichment = 9.5, q = 0.027) and ultraviolet radiation
(CDO1, CYP1A1, FOS, and GCH1, fold enrichment = 7.6,
q = 0.037, Fig. 1c, Additional file 2: Table S4). Both of
these functional enrichments included the genes
CYP1A1, FOS, and GCH1. Additionally, downregulated
transcripts were enriched for functioning in blood
coagulation (GNG12, MAFF, PF4, and PLG, fold enrich-
ment = 12.5, q = 0.009) and xenobiotic metabolism
(CDO1, CYP1A1, GCH1, and PLG, fold enrichment =
8.6, q = 0.019), but no significant enrichments were
observed for upregulated transcripts alone.
Using fold changes to rank all transcripts for gene set
enrichment analysis (GSEA), we observed significant
enrichment for upregulation of gene sets involved in
chromatin regulation (q < 0.05, Fig. 2, Additional file 2:
Table S5). In other words, genes associated with chro-
matin regulation tended to be ranked toward the top of
the distribution of fold change in ASD cord blood. Chro-
matin gene sets upregulated in ASD included DNA
methylation (23 leading edge (LE) transcripts, normal-
ized enrichment score (NES) = 2.16, q = 0.009), conden-
sation of prophase chromosomes (24 LE transcripts,
Table 2 Demographic characteristics of children and their parents in the EARLI study, stratified by child diagnosis
Child 36 month outcome
ASD (n = 18) Non-TD (n = 48) TD (n = 43) p valuea
Child male gender, n (%) 13 (72.2) 23 (47.9) 19 (44.2) 0.13
Child race and ethnicity, n (%)b 0.02h
White (European or Middle Eastern) 6 (35.3) 23 (48.9) 24 (55.8)
Black/African-American 3 (17.6) 8 (17) 1 (2.3)
Asian or Pacific Islander 2 (11.8) 5 (10.6) 0 (0)
Hispanic White 2 (11.8) 3 (6.4) 3 (7)
Hispanic Non-White 2 (11.8) 7 (14.9) 8 (18.6)
Multiracial 2 (11.8) 1 (2.1) 7 (16.3)
Mother age (years), mean (SD) 34.4 (4) 33.8 (4.3) 34.7 (5) 0.60
Father age (years), mean (SD) 35.4 (6.8) 35.7 (5) 36.2 (6.4) 0.88
Mother prepregnancy BMI, mean (SD)c 29.4 (7.1) 27.4 (7) 27.9 (7.2) 0.60
Mother smoking by urine cotinine, n (%)d 1 (6.3) 1 (2.3) 0 (0) 0.30
Mother bachelor’s degree +, n (%) 8 (44.4) 28 (58.3) 29 (67.4) 0.26
Father bachelor’s degree +, n (%)e 7 (38.9) 28 (62.2) 25 (58.1) 0.24
Own home, n (%) 8 (44.4) 31 (64.6) 36 (83.7) 0.01h
Cesarean delivery, n (%)f 9 (56.3) 17 (39.5) 12 (35.3) 0.38
Gestational age (weeks), mean (SD) 39.2 (1.4) 39.4 (1.5) 39.1 (1.5) 0.70
Birth weight (kg), mean (SD)g 3.5 (0.6) 3.5 (0.6) 3.5 (0.6) 1.00
ASD autism spectrum disorder, Non-TD non-typically developing, TD typically developing
ap values from Fisher’s exact test for categorical variables and one-way ANOVA for continuous variables
bFrequency missing = 1 ASD, 1 Non-TD
cFrequency missing = 1 Non-TD
dFrequency missing = 2 ASD, 4 Non-TD, 3 TD
eFrequency missing = 3 Non-TD
fFrequency missing = 2 ASD, 5 Non-TD, 9 TD
gFrequency missing = 1 TD
hNominally-significant association with child diagnosis
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NES = 2.11, q = 0.007), nucleosome assembly (24 LE
transcripts, NES = 1.96, q = 0.026), histone deacetylase
(HDAC)-mediated deacetylation (30 LE transcripts,
NES = 1.90, q = 0.040), and polycomb-repressive complex
2 (PRC2)-mediated methylation (22 LE transcripts,
NES = 1.89, q = 0.002). Additionally, the gene set for the
autoimmune disease systemic lupus erythematosus was
significantly upregulated (45 LE transcripts, NES = 2.13,
q = 0.003). Most of the genes associated with these sets
compose a cluster of histone genes located at the 6p22.2
locus, which was also enriched (27 LE transcripts, NES =
2.15, q = 0.007). The above findings of differential
expression across two prospective cohorts suggest tran-
scriptional dysregulation in environmentally responsive
genes is present at birth in cord blood of high-risk
subjects later diagnosed with ASD.
Non-TD-associated differential gene expression in cord
blood
To assess the specificity of ASD-associated transcrip-
tional differences in cord blood, we also examined differ-
ential expression between cord blood samples from
infants later classified as Non-TD compared to TD at
36 months. Meta-analysis results showed no transcripts
differentially expressed at a conservative FDR q value <
0.05. Under the thresholds of log2(fold change) > 0.1 and
nominal p value < 0.01, 66 transcripts were differential,
with 38 upregulated and 28 downregulated (Non-TD
n = 92, TD n = 120, Fig. 3a, Additional file 2: Table S6).
The median absolute log2(fold change) was 0.12. The
gene with the greatest fold change between Non-TD and
TD subjects was TAS2R46 (log2(fold change) = 0.37,
standard error = 0.12, Fig. 3b, Table 4). Further, the
Fig. 1 Identification and function of ASD-associated differentially expressed genes in cord blood from two high-risk prospective studies. Gene
expression in umbilical cord blood samples from subjects with typical development (n = 120, 59 male/61 female) or those diagnosed with ASD at
age 36months (n = 59, 43 male/16 female) was assessed by expression microarray. SVA was performed to control for technical and biological
variables including sex and array batch. Differential expression analysis was carried out separately by study and combined in a meta-analysis. a
Identification of 172 differentially expressed genes in meta-analysis (178 probes, log2(fold change) > 0.1, p < 0.01). b Fold change in gene
expression for top 20 differentially expressed genes sorted by meta-analysis log2(fold change) and plotted for individual studies and meta-
analysis. c ASD-associated differentially expressed genes were analyzed for functional enrichment with WebGestalt using the hypergeometric test
and compared to all genes annotated to the array. Significantly enriched ontology terms are shown (FDR q < 0.05). d ASD-associated differentially
expressed genes belonging to significantly enriched ontology terms are listed
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Table 3 Top 20 ASD-associated differentially expressed genes by log2(fold change) in meta-analysis
Probe ID Gene symbol MARBLES EARLI Meta-analysis
log2(FC) p value log2(FC) p value log2(FC) SE p value q value
17004333 TUBB2A 0.36 9.6E−03 0.33 2.1E−01 0.35 0.12 4.8E−03 0.75
17094496 MIR1299 0.28 6.1E−03 0.15 2.3E−01 0.23 0.08 4.3E−03 0.75
17065047 LOC389831 0.26 6.1E−03 0.16 2.4E−01 0.23 0.08 4.2E−03 0.74
17063807 TRBV11-2 0.22 1.7E−02 0.19 1.7E−01 0.21 0.08 7.0E−03 0.79
16812322 RNU6-667P 0.13 1.4E−01 0.34 4.1E−03 0.20 0.07 3.7E−03 0.73
16662296 RNA5SP42 0.22 3.1E−03 0.12 4.4E−01 0.20 0.07 3.0E−03 0.73
17079513 RNU6-748P 0.15 1.3E−01 0.26 1.5E−02 0.20 0.07 6.4E−03 0.78
16837063 SNORA76C 0.20 2.5E−02 0.19 1.5E−01 0.20 0.08 9.2E−03 0.83
16755265 MIR331 0.15 2.1E−02 0.26 7.0E−04 0.20 0.05 6.4E−05 0.47
16698226 LINC01136 0.17 3.0E−02 0.30 4.9E−02 0.20 0.07 5.4E−03 0.76
16738477 RP11-872D17.8 0.22 2.6E−03 0.12 3.2E−01 0.19 0.06 2.3E−03 0.72
16797869 HERC2P7 − 0.17 4.7E−02 − 0.22 5.4E−02 − 0.19 0.07 7.0E−03 0.79
16778413 TPTE2P5 − 0.25 4.9E−04 − 0.01 9.2E−01 − 0.19 0.06 2.3E−03 0.72
16865104 MIR519A2 − 0.28 3.5E−05 − 0.07 3.3E−01 − 0.19 0.05 1.8E−04 0.70
17113511 RNU6-154P − 0.22 1.9E−03 − 0.13 2.6E−01 − 0.20 0.06 1.4E−03 0.72
16810171 RP11-507B12.1 − 0.23 3.1E−03 − 0.16 1.8E−01 − 0.21 0.07 1.6E−03 0.72
17062251 RNA5SP241 − 0.15 5.8E−02 − 0.45 3.4E−03 − 0.21 0.07 2.6E−03 0.72
16788697 SNORD114-28 − 0.29 9.1E−03 − 0.17 2.8E−01 − 0.25 0.09 6.7E−03 0.78
16928422 CTA-390C10.10 − 0.17 9.8E−02 − 0.55 4.3E−04 − 0.29 0.09 7.2E−04 0.72
16733787 RP11-304M2.6 − 0.28 1.5E−02 − 0.40 5.3E−02 − 0.31 0.10 2.6E−03 0.72
ASD autism spectrum disorder, FC fold change, SE standard error
Fig. 2 Chromatin and autoimmune gene sets are upregulated in cord blood from ASD subjects. Meta-analysis log2(fold change) for ASD versus
TD gene expression was used to rank probes for gene set enrichment analysis (GSEA) with WebGestalt. GSEA assesses whether genes in
biologically defined sets occur toward the top or bottom of a ranked list more than expected by chance. Significantly enriched gene sets are
shown (FDR q < 0.05)
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estimated fold changes of Non-TD-associated differen-
tially expressed genes were highly correlated between
the individual studies (Pearson’s r = 0.80, p = 3.9E−16);
however, fold changes of all transcripts were weakly cor-
related (Pearson’s r = 0.01, p = 0.10, Additional file 1:
Figure S7b). Additionally, median expression of differen-
tially expressed genes was not different from other genes
on the array (MARBLES: differential = 4.48, non-differ-
ential = 4.64, p = 0.65; EARLI: differential = 4.15, non-dif-
ferential = 4.20, p = 0.90; Additional file 1: Figure S11).
Several of the 66 nominally differentially expressed
genes between Non-TD and TD cord blood samples
have been previously associated with genetic variation
or gene expression in ASD, although the overlap was
Fig. 3 Identification and functional enrichment of Non-TD-associated differentially expressed genes in cord blood. Gene expression in umbilical
cord blood samples from subjects with typical development (TD, n = 120, 59 male/61 female) or those diagnosed with Non-TD at age 3 (n = 92,
50 male/42 female) was assessed by expression microarray. SVA was performed to control for technical and biological variables including sex and
array batch. Differential expression analysis was carried out separately by study and combined in a meta-analysis. a Identification of 66
differentially expressed genes in meta-analysis (66 probes, log2(fold change) > 0.1, p < 0.01). b Fold change in gene expression for top 20
differentially expressed genes by meta-analysis log2(fold change) for individual studies and meta-analysis. c Non-TD-associated differentially
expressed genes were analyzed for functional enrichment in recently evolved genes with WebGestalt using the hypergeometric test. Significantly
enriched clades are shown (FDR q < 0.05). d Non-TD-associated differentially expressed genes specific to primates are listed
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not statistically significant (q > 0.05, Additional file 1:
Figure S9, Additional file 2: Table S2). Genetic
deficiencies in MIR4269 have been previously associ-
ated with a reduced risk for ASD [43], while DHCR24,
GNAO1, and TYMS were differentially expressed in
ASD in other studies [8, 44]. Additionally, none of the
Non-TD differentially expressed genes were known
cell type-specific genes (Additional file 1: Figure
S10, Additional file 2: Table S3) [41]. Differentially
expressed genes in Non-TD that overlap genes pre-
viously associated with ASD likely function in gen-
eral neurodevelopment.
Because genes recently evolved in primates have
been hypothesized to play a role in human neurodeve-
lopment, differentially expressed genes in Non-TD
cord blood were assessed for enrichment in recently
evolved genes by vertebrate lineages, ranging from
tetrapods to homininae using overrepresentation en-
richment analysis [48]. Non-TD-associated genes were
significantly enriched for genes recently evolved in
mammalia, theria, eutheria, boreoeutheria, euarchonto-
glires, primates, catarrhini, and hominidae, with the
greatest enrichment in primate-specific genes (fold
enrichment = 7.5, q = 2.1E−5, Fig. 3c, Additional file 2:
Table S7). Of genes that evolved in primates, SLC52A1,
SPANXN5, and TRIM49B were upregulated in Non-
TD cord blood, while FAM86C1, RASA4, RASA4B, and
TRIM73 were downregulated (Fig. 3d). In contrast,
ASD differentially expressed genes were not signifi-
cantly enriched in recently evolved genes from any of
the vertebrate lineages (q > 0.05).
After GSEA with all probes ranked by fold change in
Non-TD compared to TD subjects, we observed sig-
nificant enrichment for upregulation of sensory per-
ception gene sets (q < 0.05, Fig. 4a, Additional file 2:
Table S8). Taste receptor activity (14 LE transcripts,
NES = 2.30, q < 1E−4), metabotropic glutamate recep-
tors (17 LE transcripts, NES = 2.21, q = 4.9E−3), and ol-
factory receptor activity (105 LE transcripts, NES =
1.96, q = 0.018) gene sets were all upregulated in cord
blood from Non-TD subjects. Additionally, gene sets
that interact with the compounds quinine (19 LE tran-
scripts, NES = 2.30, q = 2.0E−3) and citric acid (22 LE
transcripts, NES = 2.17, q = 2.5E−3) were significantly
upregulated, while those interacting with indomethacin
(18 LE transcripts, NES = − 2.02, q = 0.037) and H2-
receptor antagonists (6 LE transcripts, NES = − 2.03,
q = 0.047) were downregulated. Taste receptor genes
Table 4 Top 20 Non-TD-associated differentially expressed genes by log2(fold change) in meta-analysis
Probe ID Gene
symbol
MARBLES EARLI Meta-analysis
log2(FC) p value log2(FC) p value log2(FC) SE p value q value
16761521 TAS2R46 0.43 6.7E−03 0.29 9.3E−02 0.37 0.12 1.7E−03 0.78
16846019 FAM215A 0.08 4.5E−01 0.32 9.5E−04 0.22 0.07 2.5E−03 0.85
17063807 TRBV11-2 0.30 9.4E−04 0.14 9.3E−02 0.21 0.06 4.5E−04 0.74
17094496 MIR1299 0.17 7.7E−02 0.22 2.1E−02 0.20 0.07 3.8E−03 0.91
16842217 SNORD3D 0.13 7.0E−02 0.25 2.9E−03 0.18 0.05 8.3E−04 0.74
16818580 RNA5SP415 0.16 6.8E−02 0.20 5.1E−02 0.18 0.07 7.9E−03 0.91
16846016 LRRC37A2 0.09 3.5E−01 0.24 6.4E−03 0.17 0.06 7.6E−03 0.91
16902656 RNA5SP103 0.22 3.0E−03 0.06 5.2E−01 0.16 0.06 5.5E−03 0.91
16975969 RNU6-310P 0.20 1.6E−03 0.08 2.5E−01 0.15 0.05 1.6E−03 0.78
16845957 LRRC37A4P 0.21 9.3E−03 0.11 1.1E−01 0.15 0.05 3.8E−03 0.91
16788576 SNORD113-3 0.14 1.1E−02 0.15 7.2E−03 0.14 0.04 2.0E−04 0.74
16840210 SLC52A1 0.19 3.4E−05 0.08 8.6E−02 0.14 0.03 1.7E−05 0.34
16774442 SMIM2-AS1 0.14 1.6E−03 0.14 4.8E−03 0.14 0.03 1.9E−05 0.34
16985844 PMCHL2 0.11 2.9E−02 0.17 1.4E−02 0.14 0.04 1.3E−03 0.74
16805216 ASB9P1 − 0.15 1.6E−02 − 0.13 3.6E−02 − 0.14 0.04 1.4E−03 0.74
17078751 REXO1L1P − 0.14 2.3E−03 − 0.12 1.0E−01 − 0.14 0.04 5.2E−04 0.74
16728518 FAM86C1 − 0.21 6.6E−03 − 0.08 3.1E−01 − 0.15 0.06 7.8E−03 0.91
17061129 RASA4 − 0.20 6.3E−03 − 0.09 2.7E−01 − 0.16 0.06 5.0E−03 0.91
16836858 RNU6-446P − 0.26 3.2E−03 − 0.06 5.7E−01 − 0.18 0.07 7.1E−03 0.91
16733848 RP11-326C3.7 − 0.07 4.4E−01 − 0.33 9.6E−04 − 0.20 0.07 3.8E−03 0.91
Non-TD non-typically developing, FC fold change, SE standard error
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included in these gene sets and the top Non-TD-
upregulated gene, TAS2R46, are located at the 12p13.2
locus, which was also enriched (16 LE transcripts,
NES = 2.11, q = 8.3E−3).
Comparison of ASD and Non-TD differentially expressed
genes
Eight genes were differentially expressed in both ASD
and Non-TD compared to TD subjects, which was more
than expected by chance (odds ratio = 28.3, p = 1.67E−9,
Fig. 5a). Specifically, IGLV1-40, LRRC37A4P, MIR1299,
PMCHL2, and TRBV11-2 were upregulated, while
RNU4ATAC11P, TPTE2P5, and TRIM74 were downreg-
ulated in both ASD and Non-TD subjects (Fig. 5b).
LRRC37AP, MIR1299, PMCHL2, and TRBV11-2 were
among the top upregulated genes in Non-TD subjects
(Fig. 3b). Additionally, the fold changes across all tran-
scripts were moderately correlated between the ASD
versus TD and Non-TD versus TD comparisons both
within study and in the meta-analysis (meta-analysis
log2(fold change) Pearson’s r = 0.38, p < 2.2E−16,
Additional file 1: Figure S7c-e). These findings suggest
that some ASD-associated transcriptional alterations in
cord blood are also present in Non-TD subjects.
Coexpression network analysis and cell type
deconvolution in cord blood from high-risk children
As a complementary approach to differential gene
expression analysis, we performed WGCNA to iden-
tify consensus gene coexpression modules and their
Fig. 4 Sensory perception gene sets are dysregulated in Non-TD subject cord blood. Meta-analysis log2(fold change) for Non-TD versus TD gene
expression was used to rank probes for GSEA with WebGestalt. GSEA assesses whether genes in biologically defined sets occur toward the top or
bottom of a ranked list more than expected by chance. Normalized enrichment score was plotted for significantly enriched gene sets (FDR q <
0.05) for default WebGestalt databases
Fig. 5 A subset of ASD-associated differentially expressed genes are also differentially expressed in Non-TD subjects. a Overlap of ASD-
and Non-TD-associated differentially expressed genes from meta-analysis by direction. Significance was assessed by Fisher’s exact test. b
Meta-analysis log2(fold change) in gene expression for ASD- and Non-TD-associated differentially expressed genes sorted by average
log2(fold change)
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correlations with ASD or Non-TD diagnosis and
other variables. Seventy-nine consensus coexpression
modules were identified, which ranged in size from
20 to 4137 transcripts (Additional file 1: Figure S12,
Additional file 2: Table S9, S10). Overall the module
eigengene networks were highly preserved between
MARBLES and EARLI subjects, indicating the identi-
fied consensus modules are robust (overall preserva-
tion = 0.93, Additional file 1: Figure S13). Module
eigengenes were correlated with diagnosis and demo-
graphic factors within each study, and these results
were combined in meta-analysis (Fig. 6, Add-
itional file 1: Figures S14-S16, Additional file 2: Table
S11). Across MARBLES and EARLI subjects, modules
were identified that significantly correlated with diag-
nostic group, sex, gestational age, birth weight, ethnicity,
paternal age, delivery method, and maternal smoking
(FDR q < 0.05, Fig. 6, Additional file 1: Figure S16). In
Fig. 6 Consensus modules are correlated with diagnosis and demographic factors in meta-analysis. Heatmap of meta-analysis biweight
midcorrelation Z-scores of module eigengenes with sample covariates (MARBLES: ASD n = 41, Non-TD n = 44, TD n = 76; EARLI: ASD n = 19, Non-
TD n = 47, TD n = 43). Z-scores from the individual studies were combined using Stouffer’s method with weights given by the square root of
sample n. p values were adjusted for all comparisons shown in Additional file 1: Figure S16 using the FDR method (*q < 0.05). Modules and
covariates with significant correlations are shown
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particular, gestational age, birth weight, and paternal age
were associated with more than 20 modules each, suggest-
ing that these factors have major effects on gene expres-
sion in cord blood from high-risk children. The skyblue1
module, which mostly includes genes on chromosome Y,
was significantly upregulated in ASD compared to TD
subjects (Z-score = 3.4, FDR q = 0.046, Additional file 1:
Figure S17a-b, Additional file 2: Table S11). Two of these
genes, TTTY10 and ZFY, were nominally upregulated in
ASD compared to TD subjects in this study, which is a
significant enrichment (Additional file 1: Figure S17d,
odds ratio = 33.6, p = 0.002). However, the association of
skyblue1 with ASD is likely driven by increased expression
of skyblue1 genes in males and a greater frequency of
males with ASD. Skyblue1 was significantly correlated
with sex (Z-score = − 28.1, FDR q = 2.7E−172), paternal
age (Z-score = 2.2, FDR q = 0.047), and maternal smoking
(Z-score = − 3.4, FDR q = 0.015). Probes in skyblue1
map to 21 genes, 18 of which are located only on
chromosome Y, explaining the strong upregulation in
males (Additional file 1: Figure S17c).
Because cord blood is a heterogeneous tissue com-
posed of many cell types with distinct transcriptional
profiles, we examined the proportions of 22 cell types
estimated with the CIBERSORT web tool and their
correlation with diagnostic group and demographic vari-
ables. The most prevalent cell types detected in cord
blood overall were neutrophils and naïve CD4+ T cells,
which made up 26% and 24% of whole cord blood, re-
spectively (Additional file 2: Table S12). When cell type
proportions were compared to diagnostic group and
demographic factors within each study and combined in
meta-analysis, no cell types differed between diagnostic
groups (Fig. 7a). However, cell fractions were signifi-
cantly correlated with demographic factors including
sex, gestational age, birth weight, delivery method, and
maternal smoking (FDR q < 0.05, Fig. 7b, Additional file 2:
Table S13). To determine the correspondence of consen-
sus modules with the proportions of specific cell types,
the module eigengenes were compared to the cell type
fractions followed by meta-analysis. The eigengenes for
the majority of consensus modules were strongly and
significantly correlated with the proportion of multiple
cell types (FDR q < 0.05, Additional file 1: Figure S18,
Additional file 2: Table S14). The cell types significantly
correlated with the most modules were neutrophils,
naïve CD4+ T cells, CD8+ T cells, M0 macrophages, and
plasma cells, which were associated with more than 30
modules each. In contrast, skyblue1, which was corre-
lated with diagnosis, along with sex, paternal age, and
maternal smoking, was not correlated with the propor-
tions of any examined cell type (Additional file 1:
Figures S16 and S18, Additional file 2: Table S14). As
an example, the grey60 module was positively
correlated with the proportions of naïve B cells, plasma
cells, and activated dendritic cells, but negatively
correlated with resting NK cells and neutrophils (FDR
q < 0.05, Additional file 1: Figure S18). The hub gene
for grey60 was CD79A, which encodes Igα, the B cell
antigen receptor component necessary for signal trans-
duction [52]. Interestingly, the grey60 module eigen-
gene, CD79A expression, and the proportion of
naïve B cells were all significantly upregulated dur-
ing cesarean delivery (FDR q < 0.05) and nominally down-
regulated in ASD compared to Non-TD subjects
(p < 0.05, Additional file 1: Figure S19, Additional file 2:
Tables S11 and S13). These results from coexpression
and cell type deconvolution analyses suggest that bio-
logical factors including cell type, gestational age, birth
weight, and paternal age are major drivers of interindivid-
ual variation in cord blood gene expression.
Discussion
Perinatal transcriptional alterations in ASD
Based on meta-analysis across two high-risk pregnancy
cohorts of similar design, we examined gene expression
differences in cord blood between high-risk children
who went on to develop ASD, were Non-TD, or were
TD at 36months. Significant differential gene expression
in cord blood at individual genes was not observed in
individuals who developed ASD compared to TD after
adjusting for multiple comparisons. However, significant
gene set enrichment was seen in toxic substance
response, blood coagulation, chromatin regulation, and
autoimmune response functions among genes differen-
tially expressed at a nominal level in ASD.
Environmental factors are thought to contribute to
ASD risk, especially during the perinatal period, a sensi-
tive window for neurodevelopment [53]. Genes nomin-
ally differentially expressed in cord blood from ASD
subjects, including CYP1A1 and GCH1, were signifi-
cantly enriched for functions in xenobiotic metabolism
and response to both toxic substances and ultraviolet
radiation. Notably, CYP1A1 was downregulated in ASD
cord blood and has been previously found to be tran-
scriptionally regulated in blood by toxicants that affect
neurodevelopment, including polychlorinated biphenyls
[54–56]. GCH1—which is the rate-limiting enzyme in
the synthesis of tetrahydrobiopterin, a precursor to fol-
ate, dopamine, and serotonin [57]—was also downreg-
ulated in cord blood from ASD subjects. GCH1
expression increases in response to valproic acid, an
anti-epileptic drug associated with behavioral deficits
in mice and increased risk of autism in humans after
in utero exposure [58, 59]. Interestingly, GCH1 is
genetically associated with ASD subphenotypes and is
downregulated in peripheral blood from ASD children,
and its product tetrahydrobiopterin is decreased in
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Fig. 7 Cell type proportions are correlated with demographic factors in meta-analysis. a Barplot of mean estimated proportion of each cell type
by diagnosis and study from CIBERSORT using default adult peripheral blood reference panel. b Heatmap of meta-analysis biweight
midcorrelation Z-scores of cell type proportions with sample covariates (MARBLES: ASD n = 41, Non-TD n = 44, TD n = 76; EARLI: ASD n = 19, Non-
TD n = 47, TD n = 43). Z-scores from the individual studies were combined using Stouffer’s method with weights given by the square root of
sample n. p values were adjusted using the FDR method (*q < 0.05)
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cerebrospinal fluid from ASD subjects [17, 60, 61].
These environmentally responsive genes may have
altered expression due to increased genetic susceptibil-
ity and/or early life exposure to toxicants in patients
with ASD [62, 63]. It is important to note that the en-
richment analysis identified gene sets with significant
overrepresentation, and so the differential expression
of individual genes should be interpreted cautiously.
Epigenetic modifications, such as those to DNA and
histone protein subunits, are affected by both genetic
and environmental factors and are thought to play a role
in mediating ASD risk [64, 65]. Immune dysregulation
has also been found in children with ASD, and immune
cells rely on epigenetic regulation for lineage commit-
ment and cell activation in response to infection [66,
67]. A cluster of histone genes at 6p22.2 was significantly
enriched for upregulated genes in ASD cord blood.
Genes associated with the autoimmune disease systemic
lupus erythematosus (SLE) were also upregulated, in-
cluding histone-encoding, complement pathway, and
antigen presentation genes. Epigenetic dysregulation is a
feature of SLE, including global DNA hypomethylation,
histone H3 and H4 hypoacetylation, and H3K9 hypome-
thylation in CD4+ T cells [68–70]. Notably, maternal
SLE increases risk for ASD in offspring, suggesting an as-
sociation between these two disorders [71]. Together, this
implicates both epigenetic and immune mechanisms in
ASD pathobiology.
Perinatal transcriptional alterations in Non-TD
To assess the specificity of cord blood gene expression
changes in ASD compared to other neurodevelopmental
disorders, this analysis examined transcriptional differ-
ences in Non-TD compared to TD subjects across the
two studies. While no single genes were significantly
differentially expressed in Non-TD subjects after adjust-
ing for multiple comparisons, sets of functionally related
genes were enriched among nominally differentially
expressed genes. Significantly enriched gene sets in-
cluded sensory perception and primate-specific genes.
The top upregulated gene in Non-TD cord blood was
TAS2R46, encoding a member of the taste 2 receptor
(TAS2R) family, which was included in the top upregu-
lated gene set, taste receptor activity. Upregulated genes
in this gene set were primarily other TAS2Rs located at
the 12p13.2 locus. TAS2Rs are G protein-coupled recep-
tors (GPCRs) highly expressed in taste receptor cells and
are associated with the perception of bitter taste [72].
Interestingly, individuals with attention-deficit/hyper-
activity disorder and epilepsy have previously been found
to perceive bitter tastes more intensely than healthy
controls [73, 74]. TAS2Rs are also expressed in blood leu-
kocytes, where they function in chemosensation of food-
borne flavor compounds and response to food uptake
[75]. Further, TAS2Rs are upregulated in leukocytes from
asthma patients and levels of lipopolysaccharide-induced
pro-inflammatory cytokines are decreased by TAS2R ago-
nists [76]. Taste receptor upregulation may reflect altered
chemosensation in the immune and nervous systems in
Non-TD subjects.
Differentially expressed genes in cord blood from
Non-TD subjects included genes recently evolved in pri-
mates and genes that function in neurodevelopment.
Primate-specific genes originated at a similar evolution-
ary time that the neocortex expanded and have biased
expression for the fetal neocortex in humans [48].
RASA4 is a fetal-biased primate-specific gene that was
also one of the top downregulated genes in Non-TD
subjects. RASA4 is a GTPase-activating protein in the
Ras signaling pathway that functions in the activation of
T cells, mast cells, and macrophages [77–79]. Children
with Non-TD were also observed to have downregula-
tion of GNAO1, encoding a G protein alpha subunit
important for neurodevelopment and synaptic signaling.
Mutations in GNAO1 are associated with epileptic en-
cephalopathy, involuntary movements, and intellectual
disability [80, 81]. Additionally, missense mutations and
downregulation of GNAO1 in lymphocytes occur in indi-
viduals with schizophrenia [82, 83]. In individuals with
ASD, GNAO1 is upregulated in postmortem cortex [6].
Further, GNAO1 is required in mast cells for toll-like re-
ceptor 2-mediated pro-inflammatory cytokine release,
suggesting GNAO1 functions in cell signaling in both
the nervous and immune systems [84].
Cord blood as a window into transcriptional alterations
specific to ASD
Umbilical cord blood gene expression offers a unique
snapshot of molecular differences in perinatal life, a crit-
ical window for neurodevelopment [85]. Hematopoietic
cells in the blood are actively differentiating and respond-
ing to environmental cues, such as pathogens and xenobi-
otics [86, 87]. Epigenetic marks written during this period,
which reflect short-term transcriptional activity, have the
potential to have long-term effects on gene regulation and
cell function [88, 89]. Signals from the immune system
cross the blood-brain barrier during gestation and influ-
ence the development of the brain [90]. Toxicant exposure
during gestation can also impact brain development [91,
92]. In this study, genes involved in toxic substance re-
sponse, xenobiotic metabolism, and chromatin regulation
were altered in cord blood from subjects diagnosed with
ASD at 36months. Transcriptional differences in cord
blood from ASD and Non-TD subjects compared to TD
subjects were largely independent, with only 8 genes in
common. Enriched gene sets associated with Non-TD ex-
pression included sensory perception and primate-specific
genes and did not overlap with ASD expression gene sets.
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Further, genes associated with ASD in previous studies of
genetic variation and gene expression had few overlaps
with ASD-associated genes in cord blood [6, 8, 42–44].
Instead, cord blood ASD genes likely represent tissue-
specific environmentally responsive genes that may reflect
in utero exposures and long-term altered neurodevelop-
mental outcomes.
Major factors contributing to transcriptional variability in
whole cord blood
While the purpose of this study was to identify changes in
cord blood gene expression associated with ASD and
Non-TD diagnosis, we also identified biological factors as-
sociated with transcription variation in cord blood,
including gestational age, birth weight, paternal age, and
cell type composition. Gestational age was correlated with
many consensus gene coexpression modules in cord
blood, and it likely reflects ongoing differentiation and ex-
pansion of hematopoietic cells captured at different devel-
opmental timepoints. Specifically, gestational age was
positively correlated with the estimated proportion of
neutrophils and negatively correlated with the propor-
tions of CD8+ T cells, naïve CD4+ T cells, and resting
mast cells, suggesting alterations in these cell types
are contributing to variability in gene expression re-
lated to gestational age. Notably, birth weight was
correlated with many of the same gene coexpression
modules as gestational age and is itself correlated
with gestational age, so modules associated with birth
weight likely reflect gestational age as well.
A mostly independent set of coexpression modules
were correlated with paternal age. Increased paternal age
has previously been associated with global changes in
transcription in peripheral blood lymphocytes, including
a downregulation of genes involved in transcriptional
regulation and a decrease in the distribution of gene
expression variance [93]. Interestingly, both increased
paternal age and decreased gene expression variance
have also been associated with ASD [93, 94]. The mech-
anism for the effect of paternal age on transcription is
still unclear, but previous studies have observed in-
creases in telomere length and de novo mutations and
alterations in DNA methylation at specific genes in
offspring from older fathers [95–97].
The factor with the strongest association with cord
blood gene expression was cell type composition, as ob-
served previously [98]. The cell types whose proportions
correlated with the most modules were neutrophils,
naïve CD4+ T cells, CD8+ T cells, M0 macrophages, and
plasma cells. Neutrophils and naïve CD4+ T cells were
also the most prevalent cell types in cord blood. The
strong correlation of estimated cell type proportions
with coexpression modules suggests that variability
between samples in cell type composition is contributing
a large portion of the transcriptional signal measured in
whole cord blood. Overall, the large impact of biological
factors on gene expression in a bulk tissue such as cord
blood makes detecting differentially expressed genes
associated with a heterogeneous disorder such as ASD
practically difficult. Future studies should take care to
reduce these sources of noise, by isolating specific cell
populations, selecting subjects with similar gestational
and paternal age, or focusing on more narrow ASD
endophenotypes [99].
Limitations
Cord blood samples from two enriched autism risk preg-
nancy cohort studies were analyzed together to improve
the power to detect differential gene expression between
ASD and TD individuals. Meta-analysis substantially in-
creased the total number of ASD and Non-TD subjects;
however, the study was not adequately powered to
detect moderate differences at a single gene level after
correcting for multiple comparisons. We have included
a supplemental power calculation for future studies
based on our findings (Additional file 1: Figure S20).
Differential genes used in the enrichment analysis also
did not meet multiple comparison-corrected statistical
significance. Lack of statistical evidence of individual
differential genes does not eliminate the potential of
identifying a biologically significant gene set enrichment
across diagnostic groups; however, the results should be
interpreted cautiously. ASD is a heterogeneous disorder,
and this may mask differential expression. The two
cohort studies coordinated classifying participants into
ASD, Non-TD, and TD diagnostic groups using the
same metrics to improve consistency between the stud-
ies. Nonetheless, it is possible that heterogeneity within
ASD remains in this study without further breaking
down the group into subtypes.
The two cohorts used the same platform to measure
the RNA expression levels and were subject to the
limitations in transcript coverage and measurement pre-
cision of the microarray platform. Transcripts not
covered by a probe on the array were not analyzed in
this study, and targeted quantitative analysis in the
general population would be needed to validate specific
transcriptional changes as ASD risk biomarkers. A cord
blood cell type gene expression reference panel was not
available at the time of analysis, and so samples were
deconvoluted using an adult panel. Future studies should
incorporate a cord blood-specific cell type deconvolution
method to improve accuracy. Additionally, genetic,
epigenetic, and environmental variation is known to
impact both gene expression and ASD risk, but this was
not investigated in this study. Future studies that
integrate cord blood gene expression with genetic,
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epigenetic, and environmental factors will be important
to improve understanding of ASD etiology.
Conclusions
In the first study to investigate gene expression in cord
blood from high-risk newborns later diagnosed with ASD,
we identified nominally statistically significant transcrip-
tional alterations specific to ASD, which were enriched for
toxic substance response and epigenetic regulation func-
tions. Differentially expressed genes in ASD had few over-
laps with those identified in cord blood from newborns
with other non-typical neurodevelopmental outcomes in
this high-risk population. Instead, Non-TD-associated
genes were enriched for sensory perception functions and
primate-specific genes. Further, coexpression and cell type
analyses revealed that gestational age, birth weight, pater-
nal age, and cell type composition have large impacts on
variability in gene expression measured in whole cord
blood.
A strength of this high-risk prospective pregnancy
cohort design was the observation of gene expression at
birth, prior to the onset of symptoms, diagnosis, and
treatment. Perinatal life is a critical period for neurode-
velopment, where environmental stressors could have
long-term impact. Additionally, ASD-associated differen-
tial expression was meta-analyzed across two independ-
ent studies with harmonized methods and compared
with expression changes in other subjects with non-
typical neurodevelopment. Finally, cord blood is an
accessible tissue that reflects the perinatal environment,
and ASD-associated gene expression changes in cord
blood may have potential as a predictive biomarker.
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